Novartis sees GSK's cancer drugs as potential blockbusters
April 22, 2014 at 09:44 AM EDT
Novartis believes GlaxoSmithKline's cancer drugs Votrient, Tafinlar and Mekinist could have more than $1 billion in sales each, the head of the Swiss company's pharmaceutical unit said on Tuesday.
